Carmila S.A. (CARM.PA)

Compare

17.08

-0.06

(-0.35%)

At close: March 12 at 5:35:27 PM GMT+1

Carmila: Changes to the Composition of the Board of Directors Following the Change in the Permanent Representative of PREDICA

PARIS, February 24, 2025--Regulatory News: Predica, a director of Carmila (Paris:CARM), decided on 17 February 2025 to appoint Florence Habib-Deloncle, Head of Real Estate in Predica's Investment Department, as its new permanent representative on Carmila's Board of Directors, replacing Emmanuel Chabas.

Business Wire 16 days ago

CRMIF
Carmila SA (CRMIF) Full Year 2024 Earnings Call Highlights: Strong Leasing Activity and ...

Carmila SA (CRMIF) reports robust financial performance with significant net rental income growth and strategic initiatives driving future prospects.

GuruFocus.com 27 days ago

CARM.PA
-0.35%
Carmila: Launch of a Share Buyback Program for €10 Million

PARIS, February 12, 2025--Regulatory News: Carmila (Paris:CARM) has signed a cash share buyback mandate with an investment service provider for a maximum amount of €10 million.

Business Wire 28 days ago

CRMIF
Carmila: 2024 Annual Results: Sustained Growth Driven by the Acquisition of Galimmo and Strong Leasing Momentum

BOULOGNE-BILLANCOURT, France, February 11, 2025--Regulatory News: Carmila (Paris:CARM):

Business Wire 29 days ago

CRMIF
Carmila: Information Concerning the Total Number of Voting Rights and Share

PARIS, February 10, 2025--Regulatory News: Carmila (Paris:CARM):

Business Wire 30 days ago

CRMIF
Carmila: Resources Devoted to the Liquidity Contract as of 31 December 2024

PARIS, January 14, 2025--Regulatory News: At 31 December 2024, resources made available for the liquidity agreement concluded by Carmila (Paris:CARM) with Kepler Chevreux were the following:

Business Wire last month

CRMIF
Carmila Will Publish Its 2024 Full-year Results on Tuesday, February 11, 2025, After Market Close

PARIS, January 09, 2025--Regulatory News: Carmila (Paris:CARM) will publish its 2024 full-year results on Tuesday, February 11, 2025, after market close and will present the 2024 full-year results on Wednesday, February 12, 2025, at 09:00 am CET.

Business Wire 2 months ago

CRMIF
Carmila: Third-quarter 2024 Financial Information

PARIS, October 17, 2024--Regulatory News: Carmila (Paris:CARM):

Business Wire 4 months ago

CRMIF
Successful Completion of Tender Offer on Carmila’s Bonds With €200,100,000 of Bonds Tendered

PARIS, September 24, 2024--Regulatory News: Carmila (Paris:CARM) successfully completed its tender offer, announced on 16 September 2024, on the following series of existing notes:

Business Wire 5 months ago

CRMIF
Carmila Successfully Issues Inaugural €300M 7-Year Green Bond, Paying a Fixed Annual Coupon of 3.875%

PARIS, September 17, 2024--Regulatory News: Carmila (Paris:CARM) today issued its first green bond for a total amount of €300 million. With a maturity of just over seven years, the bonds fall due on 25 January 2032 and pay an annual coupon of 3.875%. The financing was raised at a spread of 160 basis points above the benchmark rate with no issue premium.

Business Wire 5 months ago

CRMIF
Carmila Announces the Launch of a Tender Offer on Its Existing Notes Maturing in May 2027, March 2028, October 2028 and April 2029, and Announces Its Intention to Issue New Notes

PARIS, September 16, 2024--Regulatory News: Carmila (Paris:CARM) announces today the launch of a tender offer on the following series of existing notes:

Business Wire 5 months ago

CRMIF
Carmila: Information Concerning the Total Number of Voting Rights and Share, Provided Pursuant to Article L.233-8 II of the Code de commerce (French Commercial Code) and Article 223-16 of the Règlement général de l’Autorité des marchés financiers

PARIS, September 09, 2024--Regulatory News: Carmila (Paris:CARM):

Business Wire 5 months ago

CRMIF
Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended June 30, 2024, and highlighted recent business updates.

PR Newswire 6 months ago

CARM

CRMIF
Carmila: Closing of the Acquisition of a Stake of 7% of Galimmo SCA from Capimmo

PARIS, July 25, 2024--Regulatory News: Carmila (Paris:CARM) announces completion of the acquisition of 7% of the share capital of Galimmo SCA for a total consideration of 27 million euros, or 11.93 euros per share.

Business Wire 7 months ago

CRMIF
Carmila: 2024 Half-Year Financial Report Available

PARIS, July 24, 2024--Regulatory News: Carmila (Paris:CARM) has made available to the public and filed with the French financial markets authority (Autorité des Marchés Financiers) its 2024 Half Year Financial Report.

Business Wire 7 months ago

CRMIF
Carmila: 2024 Half-Year Results

PARIS, July 24, 2024--Regulatory News: Carmila (Paris:CARM):

Business Wire 7 months ago

CRMIF
Carmila: Resources Devoted to the Liquidity Contract as of 30 June 2024

PARIS, July 05, 2024--Regulatory News: At 30 June 2024, resources made available for the liquidity agreement concluded by Carmila (Paris:CA) with Kepler Cheuvreux were the following:

Business Wire 8 months ago

CRMIF
Carmila: Closing of the Acquisition of Galimmo SCA

PARIS, July 01, 2024--Regulatory News: Carmila (Paris:CARM) announces the closing of the acquisition of 93% of the share capital of Galimmo SCA for a total consideration of 272 million euros, or 9.02 euros per share.

Business Wire 8 months ago

CRMIF
Carmila: Potential Stake Increase in Galimmo SCA to 99.9%

PARIS, July 01, 2024--Regulatory News: On June 28, 2024, Carmila (Paris:CARM) granted to an entity managed by Primonial REIM France a put option to sell its entire 7% stake in Galimmo SCA, exercisable1 until July 30, 2024, for approximately €27 million (that is €11.93 per share).

Business Wire 8 months ago

CRMIF
Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended March 31, 2024, and highlighted recent business updates.

PR Newswire 9 months ago

CARM

CRMIF

Performance Overview

Return	CARM.PA	CAC 40
YTD	+6.62%	+8.24%
1-Year	+14.22%	-1.22%
3-Year	+37.87%	+27.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Carmila S.A. (CARM.PA)

Carmila: Changes to the Composition of the Board of Directors Following the Change in the Permanent Representative of PREDICA

Carmila SA (CRMIF) Full Year 2024 Earnings Call Highlights: Strong Leasing Activity and ...

Carmila: Launch of a Share Buyback Program for €10 Million

Carmila: 2024 Annual Results: Sustained Growth Driven by the Acquisition of Galimmo and Strong Leasing Momentum

Carmila: Information Concerning the Total Number of Voting Rights and Share

Carmila: Resources Devoted to the Liquidity Contract as of 31 December 2024

Carmila Will Publish Its 2024 Full-year Results on Tuesday, February 11, 2025, After Market Close

Carmila: Third-quarter 2024 Financial Information

Successful Completion of Tender Offer on Carmila’s Bonds With €200,100,000 of Bonds Tendered

Carmila Successfully Issues Inaugural €300M 7-Year Green Bond, Paying a Fixed Annual Coupon of 3.875%

Carmila Announces the Launch of a Tender Offer on Its Existing Notes Maturing in May 2027, March 2028, October 2028 and April 2029, and Announces Its Intention to Issue New Notes

Carmila: Information Concerning the Total Number of Voting Rights and Share, Provided Pursuant to Article L.233-8 II of the Code de commerce (French Commercial Code) and Article 223-16 of the Règlement général de l’Autorité des marchés financiers

Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Carmila: Closing of the Acquisition of a Stake of 7% of Galimmo SCA from Capimmo

Carmila: 2024 Half-Year Financial Report Available

Carmila: 2024 Half-Year Results

Carmila: Resources Devoted to the Liquidity Contract as of 30 June 2024

Carmila: Closing of the Acquisition of Galimmo SCA

Carmila: Potential Stake Increase in Galimmo SCA to 99.9%

Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Performance Overview